Navigation Links
The First Dedicated Breast Cancer Cell Line Transfection Reagent
Date:4/3/2013

MADISON, Wis., April 3, 2013 /PRNewswire/ -- Mirus Bio has expanded its transfection expertise with the development of the TransIT-BrCa Transfection Reagent a high performance, low toxicity, DNA transfection reagent specifically formulated for breast cancer cell types. This new reagent offers users:

  • Superior DNA Delivery—Achieve high expression levels in breast cancer cell types including: MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, T47D.
  • Formulated for Low Cellular Toxicity—Maintain cell density and reduce experimental biases due to toxicity.
  • Scientifically Proven—Developed by Mirus Bio scientists with nearly 2 decades of gene delivery expertise.

(Logo: http://photos.prnewswire.com/prnh/20100818/CG52502LOGO)

Mirus Bio is dedicated to advancing breast cancer research. In addition to providing scientists with state-of-the-art transfection reagents Mirus will donate a portion of every sale of TransIT-BrCa Transfection Reagent to the Breast Cancer Research Foundation.

Visit www.mirusbio.com for all your transfection needs including data, protocols, technical support or to place an order.

About Mirus Bio LLC –

ONE FOCUS: TRANSFECTION
Every transfection product offered by Mirus Bio is the result of scientific discovery and development from an in-house team of organic chemists, molecular biologists, cell biologists and biochemists. Almost two decades after its founding, transfection continues to be the focal point and passion of Mirus, giving researchers the most reliable products and expertise.


'/>"/>
SOURCE Mirus Bio LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
2. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
3. First Time in Philadelphia Is a Success for Pittcon 2013 (Summary Report)
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. Medifirst Solutions, Inc. Announces Further Update To Shareholders
6. BioMed Realty Trust Declares First Quarter 2013 Common Stock Dividend
7. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
8. First-To-File Patent Law Is Now In Effect, But What Does it Mean?
9. First Southeast Venture Philanthropy Summit Set In NC
10. Rigaku Raman Unveils Upgraded FirstGuard Handheld Analyzer with Industry’s Only 1064nm Wavelength Capabilities
11. First 3D Heads-Up Cataract Surgery Performed in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Lithuania, announced today that they have entered into a multiyear collaboration to identify ... CRISPR researchers with additional tools for gene editing across all applications. , Under ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):